Published in Clin Obstet Gynecol on March 01, 1968
Thrombosis in patients with the lupus anticoagulant. Ann Intern Med (1980) 4.02
Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A (1977) 2.79
The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood (1969) 2.61
Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med (1984) 2.26
Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res (1990) 1.90
Intravascular coagulation in fulminant meningococcemia. Ann Intern Med (1967) 1.86
Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med (1984) 1.78
Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem (1992) 1.77
Acquired inhibitors of blood coagulation. Prog Hemost Thromb (1972) 1.74
Studies of the activation of factor VII bound to tissue factor. Blood (1996) 1.62
Synthesis of intrinsic factor X activator. Inhibition of the function of formed activator by antibodies to factor VIII and to factor IX. Biochemistry (1970) 1.62
Factor V activity of platelets: evidence for an activated factor V molecule and for a platelet activator. Blood (1977) 1.50
A plasma protein C activity assay suitable for a clinical laboratory. Its use to measure activity in hereditary and acquired deficiency states. Am J Clin Pathol (1987) 1.44
A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem (1981) 1.40
Bleeding time after aspirin in disorders of intrinsic clotting. N Engl J Med (1969) 1.40
Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery. J Clin Invest (1979) 1.37
Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. J Biol Chem (1981) 1.37
Hemophilia A: polymorphism detectable by a factor 8 antibody. Science (1969) 1.32
Anti-prothrombin antibodies and the lupus anticoagulant. Blood (1988) 1.22
Hemophilia B: characterization of genetic variants and detection of carriers. Blood (1977) 1.20
Trousseau's syndrome. West J Med (1993) 1.19
Defibrination after brain-tissue destruction: A serious complication of head injury. N Engl J Med (1974) 1.17
Hemophilia prophylaxis with factor VIII concentrate. Arch Intern Med (1970) 1.16
Formation of intrinsic factor-X activator activity, with special reference to the role of thrombin. Br J Haematol (1971) 1.16
Studies of the mechanism for enhanced cell surface factor VIIa/tissue factor activation of factor X on fibroblast monolayers after their exposure to N-ethylmaleimide. Thromb Haemost (1994) 1.15
The blood clotting properties of rabbit peritoneal leukocytes in vitro. Thromb Diath Haemorrh (1967) 1.15
Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci U S A (1988) 1.15
Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood (1985) 1.13
Albinism and abnormal platelet function. N Engl J Med (1971) 1.08
Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci U S A (1991) 1.07
Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood (1979) 1.07
Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood (1987) 1.05
Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest (1979) 1.04
The basalis of the primate endometrium: a bifunctional germinal compartment. Biol Reprod (1989) 1.03
Endotoxin-induced intravascular clotting: the need for granulocytes. Thromb Diath Haemorrh (1968) 1.02
Separation from Russell's viper venom of one fraction reacting with factor X and another reacting with factor V. Biochemistry (1969) 1.02
A monoclonal antibody to factor IX that inhibits the factor VIII:Ca potentiation of factor X activation. J Biol Chem (1985) 0.98
The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost (1991) 0.97
Consumption of serum factors and prothrombin during intravascular clotting in rabbits. Scand J Haematol (1966) 0.97
A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood (1983) 0.96
Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. J Biol Chem (1992) 0.96
Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest (1993) 0.95
A procedure for isolation of human protein C and protein S as by-products of the purification of factors VII, IX, X and prothrombin. Prep Biochem (1983) 0.95
Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood (1993) 0.95
Factor V anticoagulants: clinical, biochemical, and immunological observations. J Clin Invest (1970) 0.94
Hemostatic factors in rabbit limb lymph: relationship to mechanisms regulating extravascular coagulation. Am J Physiol (1998) 0.94
Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med (1997) 0.93
Thrombotic thrombocytopenic purpura. Serial clotting studies, relation to the generalized Shwartzman reaction, and remission after adrenal steroid and dextran therapy. Ann Intern Med (1967) 0.93
Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood (1988) 0.91
Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood (1991) 0.91
Effects of thorium dioxide upon blood clotting and platelets. I. In vitro studies. Thromb Diath Haemorrh (1966) 0.91
Activation of human factor VII by activated factors IX and X. Blood (1982) 0.90
An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations. Blood (1974) 0.89
Activation of human factor VII in the initiation of tissue factor-dependent coagulation. Blood (1986) 0.89
The plasma protamine paracoagulation test: clinical and laboratory evaluation. Am J Clin Pathol (1972) 0.87
Platelets and initiation of intrinsic clotting. Br J Haematol (1973) 0.87
Radioimmunoassays for protein C and factor X. Plasma antigen levels in abnormal hemostatic states. Am J Clin Pathol (1984) 0.87
Activation of 125I-factor IX and 125I-factor X: effect of tissue factor and factor VII, factor Xa and thrombin. Scand J Haematol (1980) 0.87
Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood (1994) 0.87
Further evidence that thrombin-activation of Factor 8 is an essential step in intrinsic clotting. Scand J Clin Lab Invest (1965) 0.86
Mechanism for diminished tissue factor expression by endothelial cells cultured with heparin binding growth factor-1 and heparin. Blood (1991) 0.86
Intravascular clotting after endotoxin in rabbits with impaired intrinsic clotting produced by a factor VIII antibody. Blood (1973) 0.86
Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood (1990) 0.86
Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood (1989) 0.85
Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activation of factor VII. Thromb Res (1978) 0.85
Increased factor 8 levels in suspected carriers of hemophilia A taking contraceptives by mouth. N Engl J Med (1966) 0.84
Disappearance of fibrinogen-131-I after endotoxin: effects of a first and second injection. Am J Physiol (1968) 0.84
Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost (1988) 0.84
Functional properties of factor VIIa/tissue factor formed with purified tissue factor and with tissue factor expressed on cultured endothelial cells. Thromb Haemost (1989) 0.84
Activation of human factor VII during clotting in vitro. Blood (1985) 0.84
Affinity purification of human brain tissue factor utilizing factor VII bound to immobilized anti-factor VII. Anal Biochem (1987) 0.83
Effects of thorium dioxide upon blood clotting and platelets. II. In vivo studies in rabbits. Thromb Diath Haemorrh (1966) 0.83
Studies of the factor Xa-dependent inhibitor of factor VIIa/tissue factor (extrinsic pathway inhibitor) from cell supernates of cultured human umbilical vein endothelial cells. Thromb Haemost (1989) 0.83
Properties of factor VIIa/tissue factor complexes in an umbilical vein model. Blood (1990) 0.83
Immunologic characterization of 12 factor VIII inhibitors. Blood (1969) 0.82
Factor XI activity and factor XI antigen in homozygous and heterozygous factor XI deficiency. Blood (1976) 0.82
Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb (1993) 0.82
Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor. Thromb Haemost (1981) 0.82
Thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med (1995) 0.82
Preoperative hemostatic evaluation: which tests, if any? Blood (1983) 0.82
The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med (1994) 0.81
Cofactor of the "lupus anticoagulant". Thromb Diath Haemorrh (1974) 0.81
Failure of fibrinogen degradation products to increase plasma fibrinogen in rabbits. Proc Soc Exp Biol Med (1973) 0.81
Platelet aggregate ratios--standardization of technique and test results in patients with myocardial ischemia and patients with cerebrovascular disease. Thromb Haemost (1977) 0.81
Evidence suggestive of activation of the intrinsic pathway of blood coagulation after injection of factor Xa/phospholipid into rabbits. Arterioscler Thromb Vasc Biol (1995) 0.81
Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin: mechanism and management. Blood (1985) 0.80
Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood (1996) 0.80
Fibrinogen synthesis in adrenalectomized rabbits. Proc Soc Exp Biol Med (1973) 0.80
Decreased inducibility of tissue factor activity on human umbilical vein endothelial cells cultured with endothelial cell growth factor and heparin. Thromb Res (1988) 0.80
A sensitive, accurate assay for extrinsic pathway inhibitor (EPI) activity in rabbit plasma: paradoxical effect of excess exogenous factor X. Thromb Res (1990) 0.80
The mandatory role of lipid in the interaction of factors 8 and 9. Proc Soc Exp Biol Med (1966) 0.79
Evidence for an essential role of tissue factor dependent blood coagulation in the pathogenesis of the local Shwartzman reaction. Blood Cells Mol Dis (1995) 0.79
Effects of Thorotrast upon the reactivity and intravascular disappearance rate of fibrinogen in the rabbit. Proc Soc Exp Biol Med (1968) 0.79
Procoagulant activity of peritoneal leukocytes: effects of cortisone and endotoxin. Am J Physiol (1978) 0.79
Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII. Blood (1978) 0.79
Heterogeneity in human prothrombin: analysis of cause. Blood (1981) 0.78
Hematologic effects of endotoxin on the macaque monkey. Surgery (1971) 0.78